Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SYS6010 dosing regimens in advanced EGFR-expressing solid tumors
CTR20242983Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of CPO301 in Nonhematologic neoplasms (2 arms), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicities, adverse events, serious adverse events, maximum tolerated dose, and recommended phase II dose and Objective response rate. Started Aug 2024; status: active.
02
Drugs
CPO301
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20242983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242983.